The US Food and Drug Administration (US FDA) has released a detailed report on six observations it reported following a recent inspection at Sun Pharmaceutical Industries plant in Dadra.
FDA Issues form 483 to Sun Pharmaceutical Industries
Shares of Sun Pharmaceutical Industries slipped 3 per cent to Rs 1,559.45 in Friday’s intra-day trade on the BSE after the US drug regulator classified the pharma major's Dadra facility as Official Action Indicated (OAI). OAI means regulatory or administrative actions are recommended.
Sun Pharma Advanced Research Company announced results of interim analysis from the PROSEEK study, a global, randomised, double blind, placebo-controlled Phase 2 study in patients with Early Parkinson’s Disease. PROSEEK compared two doses of Vodobatinib with placebo and enrolled a total of 513 patients from US, Europe and India.
Sun Pharma`s Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.
Sun Pharma issues recall of gout drug due to contamination
Sun Pharma re-enlists popular ‘Pimple Popper’ doctor for acne brand TV campaign
Enforcement Report - Week of March 6, 2024
Sun Pharma to acquire 16.33 pc stake in Surgimatix for USD 3.05 mn
Sun Pharma scouting for innovative therapies to boost India business